ECSP066534A - Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia - Google Patents

Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia

Info

Publication number
ECSP066534A
ECSP066534A EC2006006534A ECSP066534A ECSP066534A EC SP066534 A ECSP066534 A EC SP066534A EC 2006006534 A EC2006006534 A EC 2006006534A EC SP066534 A ECSP066534 A EC SP066534A EC SP066534 A ECSP066534 A EC SP066534A
Authority
EC
Ecuador
Prior art keywords
profiles
dosage forms
orals
vivo
day
Prior art date
Application number
EC2006006534A
Other languages
English (en)
Inventor
Stephen Hwang
Padmaja Shivanand
Nishit B Modi
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ECSP066534A publication Critical patent/ECSP066534A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se proveen formulaciones de oxicodona que producen perfiles de plasma en estado estable in vivo sustancialmente planos; los niveles de tolerancia relacionados con dichos perfiles y niveles de tolerancia relacionados con perfiles bifásicos no se muestran estadísticamente diferentes; los perfiles de plasma en estado estable in vivo sustancialmente planos se producen a través de formas de dosificación que tienen perfiles de liberación in vitro sustancialmente de orden cero; dichos perfiles de liberación producen bajos niveles de Cmax in vivo de dosis única los cuales pueden reducir la probabilidad de efectos secundarios adversos.
EC2006006534A 2003-10-29 2006-04-28 Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia ECSP066534A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
ECSP066534A true ECSP066534A (es) 2006-11-24

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006534A ECSP066534A (es) 2003-10-29 2006-04-28 Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia

Country Status (14)

Country Link
EP (1) EP1677798A2 (es)
JP (1) JP2007509979A (es)
KR (1) KR20060108690A (es)
CN (1) CN1933837A (es)
AU (1) AU2004285547A1 (es)
BR (1) BRPI0415639A (es)
CA (1) CA2546691A1 (es)
EC (1) ECSP066534A (es)
IL (1) IL175193A0 (es)
MA (1) MA28215A1 (es)
NO (1) NO20062398L (es)
RU (1) RU2006118323A (es)
WO (1) WO2005041968A2 (es)
ZA (1) ZA200604310B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
PL2456427T3 (pl) 2009-07-22 2015-07-31 Gruenenthal Gmbh Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
PL2456424T3 (pl) 2009-07-22 2013-12-31 Gruenenthal Gmbh Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
EP2555756B1 (en) * 2010-04-07 2018-08-22 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EA201401139A1 (ru) 2012-04-18 2015-03-31 Грюненталь Гмбх Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
KR20230124110A (ko) 2016-08-10 2023-08-24 에프. 호프만-라 로슈 아게 Akt 단백질 키나아제 저해제를 포함하는 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2483655A1 (en) * 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
RU2004134728A (ru) * 2002-05-31 2005-06-10 Алза Корпорейшн (Us) Дозированные формы и композиции для осмотической доставки различных дозировок оксикодона

Also Published As

Publication number Publication date
BRPI0415639A (pt) 2006-12-12
CN1933837A (zh) 2007-03-21
CA2546691A1 (en) 2005-05-12
EP1677798A2 (en) 2006-07-12
RU2006118323A (ru) 2007-12-10
JP2007509979A (ja) 2007-04-19
IL175193A0 (en) 2008-04-13
AU2004285547A1 (en) 2005-05-12
WO2005041968A3 (en) 2006-06-22
WO2005041968A2 (en) 2005-05-12
MA28215A1 (fr) 2006-10-02
NO20062398L (no) 2006-07-27
ZA200604310B (en) 2007-11-28
KR20060108690A (ko) 2006-10-18

Similar Documents

Publication Publication Date Title
ECSP066534A (es) Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia
CR7500A (es) Formas de dosificacion de azitromicida con efectos secundarios reducidos
CR8767A (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CR9262A (es) Formulaciones en tableta de cci-1179 oralmente biodisponibles
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
SV2003001493A (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
TW200640497A (en) Pharmaceutical formulations and methods of use
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CO6771406A2 (es) Una composición combinada
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
EA200970353A1 (ru) Комбинированное лекарственное средство
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
DK1220676T3 (da) Forebyggelse af colorektal cancer
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства